Reaction

Application Site Extravasation reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 75 reports · 1 co-occurring drugs

As of the last recalculation, Application Site Extravasation appears in 75 FAERS reports alongside 1 co-occurring drug terms. The strongest observed disproportionality signal is PEGFILGRASTIM (PRR 239.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Pegfilgrastim40239.9240.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.